These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34792282)

  • 1. Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.
    Mazzu YZ; Liao Y; Nandakumar S; Sjöström M; Jehane LE; Ghale R; Govindarajan B; Gerke TA; Lee GM; Luo JH; Chinni SR; Mucci LA; Feng FY; Kantoff PW
    Mol Oncol; 2022 Jul; 16(13):2451-2469. PubMed ID: 34792282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3β/β-CATENIN signal pathway.
    Tian X; Tao F; Zhang B; Dong JT; Zhang Z
    IUBMB Life; 2018 Mar; 70(3):224-236. PubMed ID: 29389061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
    He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
    Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical application of
    Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
    Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
    Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
    J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.
    Esposito S; Russo MV; Airoldi I; Tupone MG; Sorrentino C; Barbarito G; Di Meo S; Di Carlo E
    Oncotarget; 2015 Jul; 6(19):17121-34. PubMed ID: 25686823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
    Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
    Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.
    Little GH; Baniwal SK; Adisetiyo H; Groshen S; Chimge NO; Kim SY; Khalid O; Hawes D; Jones JO; Pinski J; Schones DE; Frenkel B
    Cancer Res; 2014 May; 74(10):2857-68. PubMed ID: 24648349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.
    Zhang D; Jiang Z; Hu J; Sun X; Zheng Y; Shen Y
    Front Immunol; 2023; 14():1117585. PubMed ID: 37251370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
    Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.